| Similar Articles |
|---|
 |
The Motley Fool
June 8, 2011 |
One Medical-Device Stock to Avoid Our investing community's latest short pick: Mako Surgical.   |
The Motley Fool
April 14, 2011
Brian Orelli |
One Step Closer to Revenue for Delcath But, between getting the Chemostat paid for in Europe and approved stateside, there's still plenty for Delcath to be worried about. |
The Motley Fool
November 3, 2011
Brian Orelli |
FDA Approves! Investors Shrug. Investors just aren't that into MELA Sciences' newly approved melanoma detection device. |
The Motley Fool
September 8, 2011
Brian Orelli |
All Approvals Are Not Created Equal MELA's EU approval for its skin cancer detector MelaFind isn't nearly as important as one stateside would be. |
The Motley Fool
August 18, 2011
Brian Orelli |
Running the Correct Trial Isn't Enough MELA Sciences' stock is up on claim that their trial meets FDA guidance, but they still need to prove that the device actually works. |
The Motley Fool
November 19, 2010
Brian Orelli |
Up 95%, but Still Risky as Heck That's an understatement for MELA Sciences. |
The Motley Fool
September 26, 2011
Brian Orelli |
Closer to Approval, Now Can MELA Find Customers? The restrictions might be too much. The company has been fighting for years to gain Food and Drug Administration approval of its melanoma detection device, MelaFind. |
The Motley Fool
October 26, 2009
Dave Mock |
A Big Upgrade for Electro-Optical Sciences This bullish call comes from more than just one analyst. The Food and Drug Administration has put Electro-Optical Sciences' melanoma detection device on the fast track. |
The Motley Fool
May 13, 2011
Brian Orelli |
FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Pharmaceutical Executive
March 1, 2012
Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
The Motley Fool
November 14, 2007
Brian Lawler |
Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years. |
The Motley Fool
November 27, 2006
Brian Lawler |
Pharmaxis Gets Good News From the FDA Fast-track designation gives this pharmaceutical stock a bump. |
Pharmaceutical Executive
June 1, 2007
Jill Wechsler |
Washington Report: Shop and Compare Insurers and payers believe that more comparative information on medical treatments will save money and improve care, but such analysis may be costly to pharma. |
The Motley Fool
August 21, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs. Take a look at: Actuate... ArthroCare... Medco Health Solutions... |
